PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.420
-0.020 (-1.39%)
Apr 28, 2026, 4:00 PM EDT - Market closed
PMV Pharmaceuticals Employees
PMV Pharmaceuticals had 54 employees as of December 31, 2025. The number of employees increased by 7 or 14.89% compared to the previous year.
Employees
54
Change (1Y)
7
Growth (1Y)
14.89%
Revenue / Employee
n/a
Profits / Employee
-$1,439,667
Market Cap
75.73M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| Pelthos Therapeutics | 92 |
| XBiotech | 85 |
| ImmuCell | 73 |
| aTyr Pharma | 60 |
| Pliant Therapeutics | 49 |
| Filana Therapeutics | 20 |
| LeonaBio | 19 |
PMVP News
- 6 days ago - PMV Pharmaceuticals Announces Board Chair Transition - GlobeNewsWire
- 7 weeks ago - PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 2 months ago - PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 6 months ago - PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewsWire
- 7 months ago - PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 8 months ago - Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types - Benzinga
- 8 months ago - PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewsWire
- 9 months ago - PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire